Vytorin in the Treatment of Alopecia Areata
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Subjects, non pregnant/lactating and over 18years old, with 40% alopecia areata will take vytorin (statin/ezetimibe) for 24 or 52 weeks and be monitored for hair regrowth.
The investigators hypothesize that Vytorin medication may have an effect on the inflammatory process of alopecia areata. Inactivating the inflammatory process may help in permitting hair regrowth in those subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
Alopecia Areata |
Drug: vytorin |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Pilot Study To Evaluate the Efficacy of Vytorin (Simvastatin +Ezetimibe) In the Treatment of Alopecia Areata |
- 20% Hair regrowth [ Time Frame: 6 months ] [ Designated as safety issue: No ]would like at least 20% regrowth within 6 months time.
- maintenance of hair [ Time Frame: 6 months ] [ Designated as safety issue: No ]Will monitor patients from week 25-52 who have had 20% hairgrowth by week 24 and determine if without the medication if they continue to have hairgrowth, remain stable or lose hair.
| Estimated Enrollment: | 30 |
| Study Start Date: | July 2011 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: No medication
After 24 weeks those who have had 20% hair growth will be randomized to continue to receive the medication or be monitored while not receiving the medication.
|
Drug: vytorin
Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
Other Name: Vytorin 10/40
|
|
Active Comparator: Vytorin
Patients will receive 10/40mg tablets daily for 52 weeks.
|
Drug: vytorin
Daily taking vytorin 10/40mg for 52 weeks by mouth.
|
Detailed Description:
Primary objective:
To evaluate the efficacy of oral simvastatin + ezetimibe (Vytorin) in treating alopecia areata in subjects 18 years and older.
Secondary objective:
To investigate the presence of heat shock proteins in alopecia areata subjects, before and after treatment with oral simvastatin.
Subjects will be asked to take vytorin 10/40 for a period of 24 or 52 weeks and monitored for progression of hair regrowth. They will have Lipids, creatinine kinase (CK), liver function tests (LFTs), obtained on baseline visit prior to starting the medication and at visit 2, week 8. LFTs will be continuously monitored at visit 4, 7, week 24 and week 40.
In case of muscular pain or tenderness the medication will be stopped immediately. In most cases, muscle symptoms and CK increases resolved when simvastatin treatment was promptly discontinued.
All adverse events will be recorded
The investigators are going to exclude:
oChildren less than 18 years
- Pregnant women
- Lactating women
- Subjects with kidney, liver or muscle disease
- Allergy to the drug or its components. Subjects with history of uncontrolled hypothyroidism, The investigators Hypothesize that this medication may have an effect on the inflammatory process of alopecia areata. Inactivating the inflammatory cascade may help in permitting hair regrowth in those subjects.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 40-80% hair loss.
- Clinical diagnosis of alopecia areata
- 18-years or older
Exclusion Criteria:
- You are less than 18 years old
- You are pregnant or planning to be pregnant during the next 12 months.
- You are nursing a child.
- You have kidney, liver or muscle disease.
- You have an allergy to Lidocaine, the study drug or its components.
- You are presently participating in another clinical trial
You are currently using, or have used within the past 3 months, the following:
- Systemic corticosteroids. (prednisone, methylprednisolone, hydrocortisone etc.)
- Immunosuppressant agents.(cyclosporine, efalizumab etc.)
- Any medication that may have interaction with Vytorin (check with the study doctor for other medications you are taking).
- You are currently using, or have used within the past 2 weeks, any topical medication for the treatment of alopecia areata
- You have an ongoing hypothyroid problem that is not being treated. If this problem is being treated then you can participate.
Contacts and Locations| United States, Florida | |
| University of Miami | Recruiting |
| Miami, Florida, United States, 33136 | |
| Contact: marc handler, md 305-243-8485 mhandler@med.miami.edu | |
| Sub-Investigator: marc handler, md | |
More Information
Publications:
| Responsible Party: | Dr. Lawrence Schachner, Chairman of department of Dermatology & Cutaneous Surgery, University of Miami |
| ClinicalTrials.gov Identifier: | NCT01520077 History of Changes |
| Other Study ID Numbers: | eprost-20100451 |
| Study First Received: | January 24, 2012 |
| Last Updated: | January 26, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Miami:
|
alopecia areata vytorin statin hair growth |
Additional relevant MeSH terms:
|
Alopecia Alopecia Areata Hypotrichosis |
Hair Diseases Skin Diseases Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 16, 2013